All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Inflarx N.V., of Jena, Germany, said it expects to raise gross proceeds of about $51 million through the sale of 1.5 million common shares offered at $34 each. The company intends to use net proceeds of the offering and cash on hand to support a phase IIb trial of its anti-C5a antibody in patients with hidradenitis suppurativa (HS) and a phase II program for the candidate in ANCA-associated vasculitis patients.